Boehringer Ingelheim’s Senvelgo (velagliflozin) Receives the US FDA’s Approval as the First Oral Liquid Medication for Diabetes in Cats
- The US FDA has approved Senvelgo (velagliflozin oral solution), the first liquid once-daily, orally administered prescription medication to improve glycemic control in cats with diabetes mellitus
- Senvelgo oral solution, a highly selective inhibitor of the sodium-glucose co-transporter 2 (SGLT2) will be available in veterinary clinics in the US in mid-October. The product is also expected to be commercially available in countries globally
- By lowering elevated blood glucose levels and reducing the risk of clinical hypoglycemia events, Senvelgo oral solution improves the clinical signs of diabetes that cats suffer as soon as one week after starting treatment
Ref: PRNewswire | Image: Boehringer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at firstname.lastname@example.org
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.